<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Relapsed or refractory acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Relapsed or refractory acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Relapsed or refractory acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Terzah M Horton, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L McNeer, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter Newburger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H386384083">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is the most common cancer in children, accounting for nearly one-third of all childhood malignancies. The World Health Organization (WHO) classification considers ALL and LBL to be the same entity, distinguished only by the primary location of the disease [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Treatment of pediatric ALL/LBL is intensive, complex, and prolonged. Using contemporary approaches, approximately 90 percent of children achieve long-term survival and only small percentages have disease that is refractory to initial treatment or that relapses (recurs) [
         <a href="#rid3">
          3,4
         </a>
         ]. For children who relapse, only half achieve long-term survival [
         <a href="#rid5">
          5
         </a>
         ], but advances in treatment options, including immunotherapy, are likely to improve these outcomes.
        </p>
        <p>
         This topic discusses management of relapsed and refractory ALL/LBL in children and adolescents.
        </p>
        <p>
         Clinical presentation, diagnosis, classification, risk group stratification, treatment, and outcomes of childhood ALL/LBL are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">
          "Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6247.html" rel="external">
          "Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H925772167">
         <span class="h1">
          DESCRIPTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with ALL/LBL are cured with contemporary treatment. However, a minority of patients do not achieve an adequate response to initial therapy or experience a disease recurrence. Initial treatment of ALL/LBL is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p>
         Definitions of relapsed and refractory ALL/LBL differ among research groups, but consensus definitions have been proposed [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary refractory ALL/LBL
         </strong>
         – Primary refractory ALL/LBL (also called treatment failure) refers to persistence of leukemic blasts in the blood, bone marrow, or any extramedullary site after four to six weeks of induction therapy [
         <a href="#rid6">
          6
         </a>
         ]. This is frequently defined as either &gt;1 percent blasts (M1 morphology) or measurable residual disease (MRD) ≥1 percent at the end of induction or the end of consolidation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment failure was reported in 2.4 percent of 44,017 children ≤18 years with previously untreated ALL/LBL, according to a retrospective analysis from 14 cooperative study groups [
         <a href="#rid7">
          7
         </a>
         ]. In that study, primary refractory ALL/LBL was associated with age &gt;6 years, leukocyte count &gt;100,000 cells/microL (&gt;100 x 10
         <sup>
          9
         </sup>
         /L), T cell leukemia, central nervous system (CNS) involvement, and 11q23 chromosomal rearrangement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a French study of 1395 children with newly diagnosed ALL/LBL, the overall risk of treatment failure was 3.8 percent [
         <a href="#rid8">
          8
         </a>
         ]. Multivariate analysis identified clinical and laboratory features associated with induction failure, using immunophenotype (B cell versus T cell), Philadelphia chromosome, and mediastinal mass to classify patients into three risk groups. Compared with the low-risk group, children in the intermediate- and high-risk groups had 7- and 28-fold increased risk for induction failure, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed ALL/LBL
         </strong>
         – Relapsed ALL/LBL refers to a recurrence of ALL/LBL at any point after achieving complete remission (CR). Relapse risk is associated with age, white blood cell (WBC) count at diagnosis, immunophenotype, leukemic blast cytogenetic/molecular findings, and the response to early treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Prognostic factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Response to initial treatment is the most powerful prognostic factor in childhood ALL/LBL [
         <a href="#rid9">
          9,10
         </a>
         ]; the level of MRD at the end of induction and/or at the end of consolidation has largely replaced morphological assessment for this purpose [
         <a href="#rid11">
          11
         </a>
         ]. Nevertheless, half of all relapses occur in children with an excellent MRD response. For B cell ALL/LBL, end-of-induction MRD is the best predictor of outcome, but for T cell ALL/LBL, end-of-consolidation MRD is a better predictor of adverse outcomes [
         <a href="#rid12">
          12
         </a>
         ]. MRD can also predict outcomes in infants with ALL/LBL [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The interval between diagnosis and relapse is prognostically important. Although the terminology and details of timing differ between cooperative groups, the following can be used for describing the timing of relapse [
         <a href="#rid14">
          14,15
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Very early
         </strong>
         – &lt;18 months
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Early
         </strong>
         – 18 months to 36 months (or the end of chemotherapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Late
         </strong>
         – ≥3 years or after completion of therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some children, an apparent late relapse of ALL/LBL reveals a distinctly different molecular profile compared with the initial presentation; such presentations may actually reflect a second leukemia, rather than relapse, and they are associated with a more favorable prognosis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3913178622">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The molecular causes of relapse differ between B cell and T cell ALL/LBL. Identifying molecular events associated with relapse may offer future therapeutic opportunities.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary refractory ALL/LBL
         </strong>
         – Pathologic features associated with induction failure, such as T cell phenotype and cytogenetic/molecular features are described separately. (See
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Prognostic factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed ALL/LBL
         </strong>
         – Relapse involves complex genetic evolution of leukemic blasts, including abnormalities that were present at initial diagnosis and effects of secondary genetic alterations. Cytogenetic and molecular features associated with adverse outcomes at initial presentation of pediatric ALL/LBL are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dominant clone at relapse can often be identified retrospectively as a minor clone that was present at initial presentation; genetic features of that clone may have contributed to chemotherapy resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Different pathophysiologic mechanisms contribute to relapse of B lineage and T lineage disease; insight into the biology of relapse may offer novel therapeutic opportunities [
         <a href="#rid17">
          17-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          B cell ALL/LBL
         </strong>
         – Relapse of B cell ALL/LBL is often associated with secondary genetic alterations in epigenetic regulators and chromatin modifiers that confer resistance to therapeutic agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         As examples, mutations in
         <em>
          CREBBP
         </em>
         are found in 20 percent of relapsed B cell ALL/LBL; this gene encodes CREB binding protein, which is a transcriptional coactivator and acetyl transferase that influences expression of many genes and is associated with an impaired response to glucocorticoids [
         <a href="#rid21">
          21
         </a>
         ]. Gain-of-function mutations in
         <em>
          NT5C2
         </em>
         , which encodes the cytosolic 5'-nucleotidase cytosolic II, were found in one-sixth of relapsed B cell ALL/LBL and confer resistance to 6-MP [
         <a href="#rid22">
          22,23
         </a>
         ]. Other somatic mutations that are enriched in relapsed B cell disease include
         <em>
          WHSC1, TP53, USH2A, NRAS, IKZF1
         </em>
         , and the DNA mismatch repair genes,
         <em>
          PMS2
         </em>
         and
         <em>
          MSH6
         </em>
         [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T cell ALL/LBL
         </strong>
         – Relapsed T cell ALL/LBL is associated with heterogeneous secondary genetic changes with chromosomal abnormalities in almost all patients [
         <a href="#rid25">
          25
         </a>
         ], but few of these mutations are actionable at present. The most common secondary abnormalities include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          NOTCH
         </strong>
         – Activation of NOTCH signaling is found in approximately 80 percent of cases of relapsed T cell ALL/LBL; it is a common finding at diagnosis, as well. Constitutive NOTCH activation is generally caused by an activating mutation in
         <em>
          NOTCH1
         </em>
         or a loss-of-function mutation in
         <em>
          FBXW7
         </em>
         [
         <a href="#rid25">
          25,26
         </a>
         ]. More than 70 percent of individuals with NOTCH activation also have loss of p16 (
         <em>
          INK4A
         </em>
         ) and p14 (
         <em>
          ARF
         </em>
         ) suppressors that are encoded in the
         <em>
          CDKN2A
         </em>
         locus; this suggests that activation of NOTCH signaling cooperates with
         <em>
          CDKN2A
         </em>
         deletions to promote oncogenesis [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Transcription factors
         </strong>
         – Chromosomal translocations that place key lymphocyte transcription factor genes under the control of T cell receptor enhancers are present in half of patients with T cell ALL/LBL. Overexpressed oncogenic transcription factors include
         <em>
          TAL1, TAL2, LYL1, OLIG2, LMO1, LMO2, TLX1 (HOX11), TLX3 (HOX11L2), NKX2-1, NKX2-2, NKX2-5, HOXA
         </em>
         genes,
         <em>
          MYC, MYB,
         </em>
         and
         <em>
          TAN1
         </em>
         [
         <a href="#rid28">
          28
         </a>
         ]. Less often, rearrangements cause loss of expression of tumor suppressor genes, such as
         <em>
          WT1, LEF1, ETV6, BCL11B, RUNX1,
         </em>
         or
         <em>
          GATA3
         </em>
         [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Chromatin modification
         </strong>
         – Mutations involving components of the PRC2 complex, which is involved in chromatin modification, are found in one-quarter of cases of relapsed/refractory (r/r) T cell ALL/LBL; most common are loss-of-function mutations and deletions of
         <em>
          AZH2
         </em>
         and
         <em>
          SUZ12
         </em>
         [
         <a href="#rid29">
          29,30
         </a>
         ].
         <em>
          PHF6
         </em>
         , a homeodomain factor with a role in the epigenetic regulation of gene expression, is mutated or deleted in one-sixth of children with T cell ALL/LBL [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Signal transduction
         </strong>
         – Genetic alterations in signal transduction pathways include mutational loss of
         <em>
          PTEN
         </em>
         , an essential regulator of the PI3K-AKT signaling pathway, in 5 to 10 percent of patients [
         <a href="#rid32">
          32
         </a>
         ] and rearrangements of
         <em>
          ABL1
         </em>
         to form gene fusions with
         <em>
          NUP214, EML1,
         </em>
         and
         <em>
          ETV6
         </em>
         in 8 percent [
         <a href="#rid33">
          33-35
         </a>
         ]. MAPK alterations are more common at relapse than at diagnosis; such mutations are often associated with resistance to glucocorticoids and MAPK inhibitors restored corticosteroid sensitivity in preclinical models [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Identification of underlying molecular events may provide future treatment opportunities for relapsed ALL/LBL. Examples might include effective (and less toxic) functional gamma secretase inhibitors for patients with NOTCH mutations or agents that target NF-kB (via proteasome inhibition), P13K/AKT/mTOR, JAK/STAT, D-type cyclins, or epigenetic changes in selected cases [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2866163560">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsed or refractory (r/r) disease should be suspected in a child with a history of ALL/LBL who has systemic signs or symptoms that are concerning for either medullary or extramedullary relapse; detection of blasts in blood, marrow, or other sites; or unexplained abnormalities on complete blood count (CBC)/differential count that may lead to testing for measurable residual disease (MRD) or other evaluations. Most relapses occur within one to three years from initial diagnosis, with symptoms similar to their initial presentation.
        </p>
        <p class="headingAnchor" id="H2870638976">
         <span class="h2">
          Clinical and laboratory evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – The clinical evaluation is similar to that for initial presentation. All children with relapsed ALL/LBL should be evaluated for involvement of both medullary (bone marrow) and central nervous system (CNS) involvement. All males should be evaluated for testicular involvement. (See
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – Defining the immunophenotype and cytogenetic/molecular features of the leukemic blasts is important for management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Microscopy, flow cytometry, cytogenetics, and molecular studies should be performed on bone marrow, blood, and/or extramedullary disease specimen. While the percentage of blasts in marrow should be determined, there is not a specific threshold required for the diagnosis of r/r ALL/LBL [
         <a href="#rid1">
          1,6,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Flow cytometry and/or immunohistochemistry distinguish B cell from T cell disease, which guides management of r/r ALL/LBL. (See
         <a class="local">
          'B cell ALL/LBL'
         </a>
         below and
         <a class="local">
          'T cell ALL/LBL'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytogenetic and molecular studies
         </strong>
         – In addition to conventional cytogenetic analyses to characterize the biology of the relapse, next-generation sequencing (NGS), DNA/RNA-based fusion gene testing, and evaluation for Philadelphia chromosome (Ph)-like molecular features can be applied to identify potentially targetable molecular lesions [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Cytogenetic and molecular findings are prognostically important and may guide therapy, as described below. (See
         <a class="local">
          'Reinduction therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initial diagnosis and classification of ALL/LBL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">
          "Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children", section on 'Diagnosis of ALL/LBL'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">
          "Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1377970537">
         <span class="h2">
          Prognostic stratification
         </span>
        </p>
        <p class="headingAnchor" id="H2591498539">
         <span class="h3">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification of adverse prognostic features is important for management of r/r ALL/LBL.
        </p>
        <p>
         Important prognostic features include time to relapse (early versus late), immunophenotype (B cell versus T cell), cytogenetic/molecular features, and site of relapse (bone marrow versus isolated extramedullary relapse). In general, better outcomes are associated with longer duration between diagnosis and relapse, isolated extramedullary relapse (compared with bone marrow relapse), and robust response to reinduction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timing of relapse
         </strong>
         – Time from initial diagnosis to relapse was the strongest predictor of survival in an analysis of 1961 patients with relapsed ALL/LBL in Children's Oncology Group (COG) clinical trials; five-year overall survival (OS) was 21 percent for early relapses (&lt;18 months after diagnosis) compared with 50 percent for late relapses (&gt;36 months after diagnosis) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Site of relapse
         </strong>
         – Isolated CNS relapse was more favorable than combined CNS and bone marrow relapse or isolated marrow relapse, with 59, 24, and 39 percent five-year OS, respectively [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical features
         </strong>
         – After adjusting for site and time of relapse, multivariate analysis of 1391 patients demonstrated that older age (&gt;10 years), presence of CNS disease at diagnosis, and T cell disease were associated with lower survival rates. Prospective studies reported similar risk factors [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment intensity
         </strong>
         – Prognosis at the time of relapse does not appear to be related to the intensity of the treatment at initial diagnosis; three-year OS was similar (36 versus 39 percent) for children who were randomly assigned to standard intensity versus augmented intensity post-induction therapy [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetic/molecular features
         </strong>
         – As with newly diagnosed ALL/LBL, cytogenetic and molecular findings are associated with outcomes for r/r disease. Outcomes of children with high-risk cytogenetic findings in relapsed B cell disease was similar to that of children with high-risk clinical features [
         <a href="#rid48">
          48
         </a>
         ]. Similarly, mutant
         <em>
          TP53
         </em>
         and other adverse features (eg,
         <em>
          TCF3::HLF
         </em>
         fusion) detected at relapse are associated with poor outcome [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3143917562">
         <span class="h3">
          Stratification schemes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognostic stratification varies among research groups. The prognostic stratification scheme that is used for an individual patient should be the same as that used in the chosen treatment protocol. We generally use the COG schema [
         <a href="#rid42">
          42,51
         </a>
         ], but the Berlin-Frankfurt-Münster (BFM) [
         <a href="#rid15">
          15
         </a>
         ] or UK [
         <a href="#rid14">
          14
         </a>
         ] stratification approaches are appropriate, if those protocols are selected.
        </p>
        <p>
         To illustrate, COG stratifies risk as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Late marrow relapse (≥36 months) of B cell disease, with end-of-induction MRD &lt;0.1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Late isolated extramedullary relapse (≥18 months) with end-of-induction MRD &lt;0.1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Late marrow relapse (≥36 months) of B cell disease, with end-of-induction MRD ≥0.1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Late isolated extramedullary relapse (≥18 months), with end-of-induction MRD ≥0.1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early marrow relapse (&lt;36 months) of B cell disease
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early isolated extramedullary relapse (&lt;18 months)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         T cell disease at any site and any timing
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1327714184">
         <span class="h1">
          FIRST RELAPSE OR PRIMARY REFRACTORY ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal outcomes are associated with adherence to a contemporary research protocol and treatment at a site with substantial experience in managing pediatric ALL/LBL (or in close consultation with an experienced pediatric hematologist/oncologist). We encourage participation in a clinical trial, whenever possible.
        </p>
        <p>
         Patients with primary refractory ALL/LBL or first relapse usually require remission reinduction therapy coupled with central nervous system (CNS) management. This is followed by consolidation therapy using immunotherapy, chemotherapy, and/or allogeneic hematopoietic cell transplantation (HCT). Some current clinical trials instead begin treatment with immunotherapy (eg,
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="115765" href="/z/d/drug information/115765.html" rel="external">
          nivolumab
         </a>
         ); at present, such an approach should only be used in the context of a research study because the long-term outcomes are not well-defined.
        </p>
        <p class="headingAnchor" id="H2442100380">
         <span class="h2">
          CNS management
         </span>
         <span class="headingEndMark">
          —
         </span>
         All children with relapsed or refractory (r/r) ALL/LBL should receive CNS therapy.
        </p>
        <p>
         CNS management involves either prophylaxis or treatment of CNS leukemic involvement, according to results from lumbar puncture (LP) and/or imaging, and it is guided by the chosen treatment protocol. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No CNS involvement
         </strong>
         – Prophylaxis using intrathecal (IT)
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         (MTX).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CNS involvement
         </strong>
         – Treatment for CNS involvement may include cranial irradiation, IT MTX, and/or "triple therapy" (ie, IT MTX,
         <a class="drug drug_pediatric" data-topicid="13197" href="/z/d/drug information/13197.html" rel="external">
          cytarabine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">
          hydrocortisone
         </a>
         ); treatment may also include systemic chemotherapy that has CNS penetration, such as high-dose MTX with
         <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">
          leucovorin
         </a>
         rescue or high-dose cytarabine.
        </p>
        <p>
        </p>
        <p>
         Management of isolated CNS relapse (ie, no other sites of relapse) is discussed below. (See
         <a class="local">
          'Isolated CNS or extramedullary relapse'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H142931593">
         <span class="h2">
          Reinduction therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with primary refractory disease or first relapse of ALL/LBL, we suggest reinduction therapy using a four-drug platform (ie, glucocorticoid,
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         , anthracycline,
         <a class="drug drug_pediatric" data-topicid="12682" href="/z/d/drug information/12682.html" rel="external">
          pegaspargase
         </a>
         ), as guided by the chosen research group protocol.
        </p>
        <p>
         Drugs, doses, and schedules vary among cooperative groups. No randomized trials have directly compared protocols for relapsed disease, and there is no preferred regimen. Various contemporary protocols are associated with similar outcomes [
         <a href="#rid14">
          14,15,49,51,52
         </a>
         ] and it is difficult to compare retrospective studies because of heterogeneous patient populations, lack of a randomized control group, and different stratification schemes and outcomes measures.
        </p>
        <p>
         Composition of the reinduction regimen, including selection of an anthracycline and glucocorticoid are discussed below. (See
         <a class="local">
          'Reinduction platform'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional agents
         </strong>
         – Other agents may be added to the four-drug platform for children with certain features, as guided by the chosen research protocol:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T cell ALL/LBL
         </strong>
         – T cell disease is associated with less favorable responses to reinduction (eg, 30 to 40 percent complete remission [CR]) [
         <a href="#rid38">
          38,53
         </a>
         ]. Some ongoing clinical trials use
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         as a component of reinduction therapy [
         <a href="#rid54">
          54-56
         </a>
         ] or add agents such as
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         to the four-drug reinduction platform [
         <a href="#rid57">
          57
         </a>
         ]. Nelarabine has been shown to improve CR rates for intermediate-risk and high-risk T cell ALL patients. (See
         <a class="local">
          'Other agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Philadelphia chromosome (Ph)-positive disease
         </strong>
         – For children with t(9;22)/
         <em>
          BCR::ABL1
         </em>
         , we add
         <a class="drug drug_pediatric" data-topicid="12618" href="/z/d/drug information/12618.html" rel="external">
          imatinib
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="120511" href="/z/d/drug information/120511.html" rel="external">
          dasatinib
         </a>
         to the four-drug reinduction platform. (See
         <a class="local">
          'Philadelphia chromosome (Ph)-positive'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ph-like ALL
         </strong>
         – For children with
         <em>
         </em>
         a
         <em>
          JAK2
         </em>
         or
         <em>
          ABL
         </em>
         -class kinase mutation, some studies add a targeted agent (eg,
         <a class="drug drug_pediatric" data-topicid="122146" href="/z/d/drug information/122146.html" rel="external">
          ruxolitinib
         </a>
         for
         <em>
          JAK2
         </em>
         mutation, tyrosine kinases inhibitors for
         <em>
          ABL
         </em>
         -class abnormalities) [
         <a href="#rid58">
          58,59
         </a>
         ], especially for children with high-risk features (eg, marked leukocytosis or age &gt;10 years), although clinical benefits are not proven [
         <a href="#rid5">
          5
         </a>
         ]. Allogeneic HCT frequently follows reinduction or induction and consolidation chemotherapy with a tyrosine kinase inhibitor (TKI).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest
         <strong>
          not
         </strong>
         using immunotherapy for reinduction, as we await results of ongoing clinical trials that are evaluating
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         (AALL1731, AALL1821),
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          inotuzumab ozogamicin
         </a>
         , and chimeric antigen receptor (CAR)-T cell therapy in patients with high-risk first relapse (NCT04276870, NCT02443831).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalization
         </strong>
         – We generally hospitalize patients until recovery of blood counts to best manage infections, transfusion support, and other complications. Prophylaxis for
         <em>
          Pneumocystis jirovecii
         </em>
         (eg, sulfamethoxazole-trimethoprim,
         <a class="drug drug_pediatric" data-topicid="13205" href="/z/d/drug information/13205.html" rel="external">
          dapsone
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12690" href="/z/d/drug information/12690.html" rel="external">
          pentamidine
         </a>
         ) is routinely given, while prophylaxis for fungal, bacterial and viral agents varies among institutions [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Response to the core reinduction regimen varies with the leukemic immunophenotype (ie, B versus T lineage), timing of relapse (ie, early versus late), and site of relapse (ie, bone marrow versus CNS or other extramedullary sites).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with first relapse of ALL/LBL have approximately 50 percent five-year overall survival (OS) [
         <a href="#rid62">
          62
         </a>
         ]. In a cooperative group study of 124 children with first relapse of ALL/LBL, CR ranged from approximately 25 percent (T cell disease) to nearly 100 percent (late relapses); MRD &lt;0.01 percent at end of induction was present in 25 percent for children with early relapses and 50 percent with late relapses [
         <a href="#rid52">
          52
         </a>
         ]. Infection-related deaths during reinduction therapy occurred in 2 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Outcomes are likely to change as results emerge from ongoing studies that incorporate immunotherapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1176230900">
         <span class="h2">
          Post-remission management
         </span>
        </p>
        <p class="headingAnchor" id="H3668810459">
         <span class="h3">
          B cell ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with r/r B cell ALL/LBL, post-remission management is guided by the risk category, which is determined by patient-specific clinical features, biology of the leukemic blasts, and response to reinduction therapy. Similar to de novo disease, response is assessed in the bone marrow and extramedullary sites at end-of-induction. (See
         <a class="local">
          'Prognostic stratification'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2900461838">
         <span class="h4">
          Low-risk B cell
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies use chemotherapy for a total of two years for children with low-risk disease.
        </p>
        <p>
         There is no consensus approach for managing low-risk r/r B cell ALL/LBL. Some experts favor UKALL R3 because of its lower cumulative doses of chemotherapy compared with other regimens [
         <a href="#rid49">
          49,51,63,64
         </a>
         ]. Other acceptable regimens include ALL-REZ-BFM 2002 [
         <a href="#rid51">
          51
         </a>
         ], COG AALL0433 [
         <a href="#rid63">
          63
         </a>
         ], or COG AALL07P1 [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p>
         Low-risk relapsed B cell ALL/LBL is associated with favorable prognosis and approximately 70 percent long-term OS. (See
         <a class="medical medical_review" href="/z/d/html/6247.html" rel="external">
          "Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3109917888">
         <span class="h4">
          Intermediate- or high-risk B cell
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with intermediate-risk or high-risk relapsed B cell ALL/LBL, consolidation therapy is guided by response to reinduction therapy.
        </p>
        <p>
         Our approach follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≤25 percent blasts
         </strong>
         – For children who achieve CR (ie, &lt;5 percent marrow blasts) or M2 marrow (5 to 25 percent blasts) at end-of-induction, we suggest post-remission treatment with
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         , rather than standard chemotherapy, particularly if the patient has not previously been treated with blinatumomab or remains CD19+ after initial blinatumomab treatment. This suggestion is based on superior survival and less toxicity compared with conventional chemotherapy in a randomized clinical trial [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A phase 3 COG trial (AALL1331) of 214 patients (age 1 to 30 years) with first relapse of B cell ALL/LBL reported that, compared with chemotherapy,
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         achieved superior OS, more patients were able to proceed to HCT, and there were fewer adverse events (AEs) [
         <a href="#rid65">
          65
         </a>
         ]. After receiving a four-drug reinduction regimen, patients were randomly assigned to two four-week cycles of blinatumomab versus two cycles of multiagent chemotherapy, each followed by allogeneic HCT. For the blinatumomab and chemotherapy arms, two-year OS rates were 71 and 58 percent, respectively (hazard ratio [HR] for mortality 0.62 [95% CI 0.39-0.98]), but disease-free survival (DFS; the primary end-point) was not significantly different (54 versus 39 percent; HR 0.70 [95% CI 0.47-1.03]). Compared with chemotherapy, patients treated with blinatumomab were more likely to proceed to transplantation (70 versus 43 percent) and achieve MRD negativity (75 versus 32 percent). There were fewer grade ≥3 AEs with blinatumomab, including infections (15 versus 65 percent), febrile neutropenia (5 versus 58 percent), sepsis (2 versus 27 percent), and mucositis (1 versus 28 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children treated with
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         , further management is guided by subsequent MRD status.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MRD-negative
         </strong>
         – If the child is MRD-negative after
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         treatment, we generally proceed to allogeneic HCT as soon as a suitable donor is identified, because the durability of remission with blinatumomab is uncertain at present. Longer follow-up of AALL1331 and other studies may find that blinatumomab can achieve long-term disease control without transplantation. (See
         <a class="local">
          'Blinatumomab (anti-CD19)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For some children with late relapse (ie, &gt;36 months) who are MRD-negative, consolidation chemotherapy alone (eg, per UKALL R3, ALL-REZ-BFM 2002, COG AALL0433) is associated with approximately 70 percent long-term OS [
         <a href="#rid49">
          49,51,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MRD-positive
         </strong>
         – We generally seek to convert children who are MRD-positive (eg, ≥0.01 percent) after receiving
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         to MRD-negative status, followed by allogeneic HCT. Leukemic blasts should be re-evaluated for expression of CD19 to avoid the possibility of not responding to further CD19-directed therapy [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Options for achieving MRD-negative status with B cell ALL/LBL include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Additional
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          Inotuzumab ozogamicin
         </a>
         (anti-CD22 monoclonal antibody); importantly, inotuzumab has been associated with sinusoidal obstruction syndrome (SOS) both pre- and post-HCT. (See
         <a class="medical medical_review" href="/z/d/html/129810.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chimeric antigen receptor (CAR)-T cell therapy (if available).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We generally proceed to allogeneic HCT after achieving MRD-negative status because the long-term durability of response with these approaches is uncertain at present. Importantly, outcomes are better when transplantation is performed when the patient is MRD-negative [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Treatment and outcomes with
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         ,
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          inotuzumab ozogamicin
         </a>
         , and allogeneic HCT are discussed below. (See
         <a class="local">
          'Treatment regimens'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &gt;25 percent blasts
         </strong>
         – For children with an M3 marrow (&gt;25 percent marrow blasts) at end-of-induction, treatment is similar to that for MRD-positive patients (above). Achieving MRD-negative status may require several additional cycles of
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         or treatment with either
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          inotuzumab ozogamicin
         </a>
         or CAR-T cell therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H304737947">
         <span class="h3">
          T cell ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consolidation therapy
         <strong>
         </strong>
         for
         <strong>
         </strong>
         children with first relapse or primary refractory T cell ALL/LBL is guided by bone marrow examination at the end of induction. Outcomes are generally less favorable for patients with relapsed T cell ALL/LBL disease, compared with relapsed B cell disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRD-negative
         </strong>
         – In general, we proceed to allogeneic HCT using the best available donor as soon as an MRD-negative CR is achieved. (See
         <a class="local">
          'Allogeneic transplantation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRD-positive
         </strong>
         <strong>
          or less than CR
         </strong>
         – For patients with T cell ALL/LBL who are MRD-positive at end-of-induction, therapeutic options include
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         , or
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         /navitoclax.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally favor
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         if it was not given during initial therapy. A COG phase 2 study (AALL07P1) suggested that
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         was associated with improved CR rates in T cell ALL/LBL [
         <a href="#rid68">
          68
         </a>
         ]. Bortezomib had an encouraging signal in COG AALL1231, particularly with lymphoblastic lymphoma, but the trial closed before the effectiveness of bortezomib for T cell lymphoblastic leukemia could be determined [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2603519109">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes for pediatric patients with relapsed or refractory (r/r) ALL/LBL have generally been poor, with long-term survival in only one-half of patients. Outcomes are related to time to relapse and site of relapse.
        </p>
        <p>
         Outcomes for relapsed ALL/LBL are associated with the duration of first complete remission (CR1) and the number of previous salvage attempts [
         <a href="#rid63">
          63,70,71
         </a>
         ]. Early relapse (ie, &lt;36 months after initial diagnosis for bone marrow relapse or &lt;18 months after initial diagnosis for isolated extramedullary relapse) are associated with inferior outcomes.
        </p>
        <p>
         Allogeneic hematopoietic cell transplantation (HCT) is the only proven curative therapy for early relapse of B cell ALL/LBL. At present, it is uncertain if patients treated with chimeric antigen receptor (CAR)-T cells or other immunotherapy can maintain long-term remission without subsequent HCT [
         <a href="#rid72">
          72
         </a>
         ]. Chemotherapy alone may be sufficient for selected patients with late relapses of B cell ALL/LBL or late isolated central nervous system (CNS) relapses of T cell ALL/LBL [
         <a href="#rid14">
          14,63
         </a>
         ].
        </p>
        <p>
         Examples of studies of r/r ALL/LBL include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          UKALL R3
         </strong>
         – In this trial, patients (1 to 18 years) were stratified into standard-, intermediate-, or high-risk groups (based on the duration of CR1, site of relapse, and immunophenotype) and randomly assigned to
         <a class="drug drug_pediatric" data-topicid="12617" href="/z/d/drug information/12617.html" rel="external">
          mitoxantrone
         </a>
         versus
         <a class="drug drug_pediatric" data-topicid="13372" href="/z/d/drug information/13372.html" rel="external">
          idarubicin
         </a>
         on days 1 and 2 of reinduction therapy [
         <a href="#rid63">
          63
         </a>
         ]. The high-risk group and patients in the intermediate-risk group who were measurable residual disease (MRD)-positive at end-of-induction (ie, ≥10
         <sup>
          -4
         </sup>
         cells) underwent allogeneic HCT. With median follow-up of seven years, progression-free survival (PFS) was 60 percent. Mitoxantrone achieved superior three-year overall survival (OS; 69 versus 45 percent) and three-year PFS (65 versus 36 percent). Among the 92 children who underwent transplantation, 63 percent remained in second CR (CR2), 14 percent died of complications, and 23 percent relapse after transplantation; among the 70 patients who continued on chemotherapy alone, 70 percent remained in CR2, 3 percent died of complications, and 27 percent relapsed [
         <a href="#rid70">
          70
         </a>
         ]. After five years, PFS was 56 percent for MRD-positive patients and 72 percent for MRD-negative patients [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Superior survival with
         <a class="drug drug_pediatric" data-topicid="12617" href="/z/d/drug information/12617.html" rel="external">
          mitoxantrone
         </a>
         in UKALL R3 must be balanced against increased cardiotoxicity; mitoxantrone is associated with a 10-fold increased risk of permanent cardiotoxicity compared with
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COG AALL01P2
         </strong>
         – This study reported that undetectable MRD (by flow cytometry) after one cycle of reinduction therapy was associated with better outcomes [
         <a href="#rid52">
          52
         </a>
         ]. Children with first bone marrow (BM) relapse (69 with early relapse and 55 with late relapse) were treated with three 35-day blocks of reinduction chemotherapy. For early versus late relapse, rates of CR2 after cycle 1 were 68 and 96 percent, respectively, and rates of MRD-positive (&gt;0.01 percent) were 75 and 51 percent. For children who were MRD-positive after block 1, MRD burden was reduced in 40 of 56 patients following blocks 2 and 3. Toxicity was acceptable during all three blocks, with 4 percent deaths from infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar results were obtained in a study (COG AALL07P1) of 146 patients who were treated with the same induction regimen plus
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ALL-REZ BFM 90
         </strong>
         – This study stratified 525 patients (&lt;19 years) into risk groups: A (early BM relapse), B (late BM relapse), and C (isolated extramedullary relapse) and were treated with alternating short-course intensive chemotherapy and cranial/craniospinal irradiation followed by maintenance therapy [
         <a href="#rid46">
          46
         </a>
         ]. Patients in the poor-prognosis groups (ie, groups A or B) were eligible for either treatment based on in vitro resistance profiles or for pilot protocols using treatments planned for a subsequent study of relapsed disease. A total of 117 patients received HCT. CR2 was achieved by 84 percent (83, 94, and 100 percent in groups A, B, and C, respectively), 5 percent died during induction, and 11 percent did not show response; 117 patients received HCT. Duration of CR1, site of relapse, immunophenotype, and transplantation were associated with event-free survival in multivariate analysis.
        </p>
        <p>
        </p>
        <p>
         Outcomes of treatment for isolated CNS or other extramedullary relapse are discussed below.
        </p>
        <p class="headingAnchor" id="H3637041590">
         <span class="h1">
          SPECIAL SCENARIOS
         </span>
        </p>
        <p class="headingAnchor" id="H2292159505">
         <span class="h2">
          Philadelphia chromosome (Ph)-positive
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(9;22)/
         <em>
          BCR::ABL1
         </em>
         rearrangement (Philadelphia chromosome) generates the constitutively active tyrosine kinase, BCR::ABL1. Ph+ ALL/LBL accounts for &lt;5 percent of children at initial diagnosis and is considered an adverse prognostic feature [
         <a href="#rid74">
          74,75
         </a>
         ]. Either B cell or T cell ALL/LBL can be Ph+. Development of BCR::ABL1 tyrosine kinase inhibitors (TKI) has greatly improved outcomes in children with Ph-positive disease.
        </p>
        <p>
         <em>
          BCR::ABL1
         </em>
         kinase domain (KD) mutation analysis (eg, T315I) should be performed. An appropriate TKI should be added to the reinduction regimen, but management is otherwise similar to that for relapsed or refractory (r/r) Ph-negative disease. Allogeneic hematopoietic cell transplantation (HCT) is generally used as first-line consolidation for relapsed Ph+ ALL/LBL, if not previously performed.
        </p>
        <p>
         Examples of mutation-guided selection of a TKI are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4496.html" rel="external">
          "Overview of the treatment of chronic myeloid leukemia", section on 'Disease resistance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2969072770">
         <span class="h2">
          Ph-like ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ph-like ALL/LBL is a subgroup of B cell ALL/LBL that occurs in approximately 15 percent of pediatric patients and is associated with unfavorable prognosis [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Management is similar to that of other Ph-negative ALL/LBL. Most cases of r/r Ph-like ALL/LBL have cytokine receptor or kinase-activating alterations (eg,
         <em>
          CRLF2
         </em>
         or
         <em>
          JAK
         </em>
         ) and ongoing studies are examining the role of JAK inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="122146" href="/z/d/drug information/122146.html" rel="external">
          ruxolitinib
         </a>
         ) or TKIs in treatment [
         <a href="#rid77">
          77-79
         </a>
         ].
         <em>
          IKZF1
         </em>
         mutations are frequent and associated with a poor prognosis; overall survival (OS) is 30 to 60 percent, with outcomes that are generally better in younger patients.
        </p>
        <p class="headingAnchor" id="H1132682168">
         <span class="h2">
          Isolated CNS or extramedullary relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with a relapse limited to the central nervous system (CNS) or another extramedullary site (eg, testis) generally have better prognosis than those with a bone marrow relapse.
        </p>
        <p>
         These children require distinctive treatment, which may include radiation therapy (RT) [
         <a href="#rid51">
          51,80,81
         </a>
         ]. Nevertheless, the greatest cause of treatment failure in these patients is a systemic (ie, bone marrow) relapse, so they also require therapy for systemic relapse, as discussed above. (See
         <a class="local">
          'First relapse or primary refractory ALL/LBL'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated CNS relapse
         </strong>
         – Children with an isolated CNS relapse (ie, no apparent systemic relapse) have better prognosis than those with a bone marrow relapse, but both require systemic and CNS-directed treatments [
         <a href="#rid80">
          80
         </a>
         ]. An Ommaya reservoir placement can be considered for frequent delivery of intraventricular CNS therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – Treatment varies according to the interval since diagnosis and institutional approach:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Late isolated CNS relapse
         </strong>
         – For late isolated CNS relapse (≥18 months after diagnosis), we favor two years of intensive chemotherapy with delayed cranial radiation (18 gray [Gy]) at around 12 months [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For late isolated CNS relapses, event-free survival (EFS) is 75 to 80 percent; treatment using intermediate- or high-dose
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13197" href="/z/d/drug information/13197.html" rel="external">
          cytarabine
         </a>
         with delayed RT (to maximize early delivery of intensive chemotherapy) is associated with approximately 50 percent longer term EFS, but substantial systemic and CNS adverse effects (AEs) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         POG 9412 reported that 12 months of intensive chemotherapy with reduced-dose cranial radiation (18 Gy) was highly effective for children with isolated CNS relapse and first complete remission (CR1) ≥18 months [
         <a href="#rid82">
          82
         </a>
         ]. Treatment included intensified systemic therapy and delay of cranial radiation for 12 months. Nearly all (97 percent) achieved CR2, and four-year EFS for patients with B cell disease was 70 percent. Compared with children who had CR1 &lt;18 months, patients with late relapse had superior four-year EFS (78 versus 52 percent). Most relapses involved the bone marrow, and three second malignancies were reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In COG AALL02P2, 118 patients with late isolated CNS relapse of B cell ALL/LBL were treated with intensified systemic therapy, triple intrathecal (IT) chemotherapy, 12 Gy cranial irradiation at 12 months, with maintenance chemotherapy continuing until 104 weeks post-diagnosis [
         <a href="#rid84">
          84
         </a>
         ]. Three-year OS and EFS were 80 percent and 64 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Early
         </strong>
         <strong>
          isolated CNS relapse
         </strong>
         – For early isolated CNS relapse (&lt;18 months after diagnosis), after achieving CR we generally proceed to allogeneic HCT with a total body irradiation (TBI) preparative regimen with a CNS boost.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Patients with early isolated CNS relapse do less well, compared with late isolated CNS relapse with 40 to 50 percent three-year OS [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Preference for allogeneic HCT for early isolated CNS relapse is based on trends toward improved outcomes using HCT rather than chemotherapy/cranial RT alone in COG AALL0433, UKALL R3, and single-institution studies [
         <a href="#rid51">
          51,83,85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ongoing studies are exploring how to reduce acute and long-term toxicities from intensive chemotherapy and cranial RT; importantly, there was an increase in treatment failures when cranial RT was reduced to 12 cGy, compared with 18 Gy in COG AALL02P2 [
         <a href="#rid86">
          86
         </a>
         ]. Chimeric antigen receptor (CAR)-T cells circulate in the cerebrospinal fluid [
         <a href="#rid87">
          87
         </a>
         ] and a clinical trial is testing this modality for isolated CNS relapse (NCT04276870). CAR-T cell therapy may be useful if the response to reinduction was suboptimal, transplantation is contraindicated, or the patient is very young (because of increased risk of long-term neurologic toxicity following cranial RT) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated extramedullary relapse
         </strong>
         – Isolated extramedullary relapse is associated with inferior outcomes compared with isolated CNS relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many patients with isolated extramedullary relapses have detectable measurable residual disease (MRD) in bone marrow at the time of relapse [
         <a href="#rid89">
          89,90
         </a>
         ]. We generally treat patients with isolated extramedullary relapse according to either POG 9412 [
         <a href="#rid82">
          82
         </a>
         ] or COG AALL02P2 [
         <a href="#rid84">
          84
         </a>
         ]. We pursue allogeneic HCT only in patients who remain MRD-positive at end-of-induction, because of the association of MRD with adverse outcomes [
         <a href="#rid91">
          91,92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Retrospective analysis of children with isolated extramedullary
         <strong>
         </strong>
         relapse reported that, for very early isolated extramedullary relapses (&lt;18 months), HCT was associated with improved long-term survival, compared with chemotherapy/RT (52 versus 20 to 30 percent) [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H372890127">
         <span class="h1">
          SECOND OR LATER RELAPSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes are inferior for second or later relapse, compared with first relapse. We encourage enrollment in a clinical trial when possible.
        </p>
        <p class="headingAnchor" id="H3049938022">
         <span class="h2">
          Multiply relapsed B cell ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of multiply relapsed ALL/LBL is guided by prior therapy. ALL/LBL that relapses after both allogeneic hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell therapy is especially challenging. We offer palliative therapy to lessen symptoms for all children [
         <a href="#rid94">
          94
         </a>
         ]. ALL/LBL that relapses after allogeneic HCT historically has had a dismal prognosis, with increased complications and long-term survival of only 25 to 30 percent in those who achieved complete remission (CR) [
         <a href="#rid95">
          95-98
         </a>
         ]. Time between transplantation and subsequent relapse is prognostic, with low survival for relapse within 6 to 12 months, but outcomes are better for those who relapse &gt;12 months after HCT and undergo a second transplant in remission [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         When ALL/LBL relapses after CAR-T cell therapy, it can be CD19+ or CD19-negative (so-called antigen escape). Mechanisms of antigen escape include point mutations, frameshift mutations, and alternative splicing of CD19 transcripts that remove the domain recognized by the CAR-T cell anti-CD19 antibody [
         <a href="#rid99">
          99,100
         </a>
         ]. Following CAR-T cell therapy, there may be an increased risk for a CD19-negative relapse or failure to achieve MRD-negativity [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         Our general approach follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CD19-negative
         </strong>
         – If the relapse is CD19-negative, we generally treat with chemotherapy, second transplant, or CD22-directed CAR-T cell therapy (NCT02315612, NCT04088864, NCT02650414), because
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         and anti-CD19 CAR-T cells are not options.
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          Inotuzumab ozogamicin
         </a>
         can be given if the blasts are CD22-positive, but it may increase the risk of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) with transplantation, particularly if multiple cycles are administered [
         <a href="#rid102">
          102,103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CD19+
         </strong>
         – If the relapse is CD19+, in addition to the options mentioned above,
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         or treatment with CD19-directed CAR-T cell therapy may be considered.
        </p>
        <p>
        </p>
        <p>
         Comprehensive genomic profiling may identify a potentially targetable gene alteration. Examples include treatment with an mTOR inhibitor (NCT01523977; NCT01614197, NCT03328104, NCT01614197), proteasome inhibitor (NCT02303821, NCT03888534, NCT03817320), CDK4/6 inhibitor (NCT03792256, NCT03515200), or BCL-2 inhibitor (NCT03236857) in combination with chemotherapy. Treatment for these patients is best performed in the context of a clinical trial for patients with multiply relapsed disease.
        </p>
        <p class="headingAnchor" id="H4104433025">
         <span class="h2">
          Multiply relapsed T cell ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination chemotherapy
         </strong>
         – Regimens that include
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         or
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         may be considered. (See
         <a class="local">
          'Other agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          Nelarabine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         (NECTAR) showed high CR rates with acceptable neurotoxicity, but concomitant administration of nelarabine and intrathecal (IT) chemotherapy should be avoided to reduce the risk of neurotoxicity; NECTAR may be more practical to administer after reinduction, especially if CNS involvement is present [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In COG AALL07P1,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         is added to a prednisone-based four-drug reinduction platform [
         <a href="#rid68">
          68
         </a>
         ]. Addition of bortezomib was effective for relapsed lymphoblastic lymphoma, but efficacy for T cell ALL is uncertain because a phase 2 study (AALL07P1) was not powered to determine efficacy and the phase 3 clinical trial was closed early [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy
         </strong>
         – Immunotherapy has promise for relapsed or refractory (r/r) T cell ALL/LBL [
         <a href="#rid105">
          105
         </a>
         ]. The CD38-directed monoclonal antibody,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         , has shown preclinical activity in T cell and early T cell precursor ALL/LBL; daratumumab combined with chemotherapy is being tested in r/r T cell ALL/LBL (NCT03384654) [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclin inhibition
         </strong>
         – The cyclin D-CDK4/6 axis is implicated in T cell leukemogenesis and clinical trials are investigating the CDK4/6 inhibitor,
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         , combined with chemotherapy (NCT03792256, NCT03515200) and
         <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">
          ribociclib
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="17063" href="/z/d/drug information/17063.html" rel="external">
          everolimus
         </a>
         (NCT03740334) [
         <a href="#rid107">
          107,108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BCL2 inhibition
         </strong>
         –
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          Venetoclax
         </a>
         (selective BCL2 inhibitor) and/or navitoclax (inhibitor of BCL-2, BCL-XL, and BCL-W) have shown single-agent activity in preclinical models, synergistic activity in ALL xenografts, and promising activity in early phase clinical studies [
         <a href="#rid109">
          109-112
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other targeted approaches are being investigated for r/r T cell ALL/LBL [
         <a href="#rid113">
          113
         </a>
         ]. NOTCH1 signaling is an attractive target because of the high frequency of mutations in this pathway. Development of gamma-secretase inhibitors that target the NOTCH1 pathway has been hampered by severe gastrointestinal toxicity, but more selective inhibitors may overcome this problem [
         <a href="#rid25">
          25,26,114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2397231947">
         <span class="h1">
          TREATMENT REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H804435957">
         <span class="h2">
          Chemotherapy
         </span>
        </p>
        <p class="headingAnchor" id="H3108217570">
         <span class="h3">
          Reinduction platform
         </span>
         <span class="headingEndMark">
          —
         </span>
         All research groups use a four-drug reinduction chemotherapy regimen (ie, glucocorticoid,
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         , anthracycline,
         <a class="drug drug_pediatric" data-topicid="120130" href="/z/d/drug information/120130.html" rel="external">
          calaspargase pegol
         </a>
         ), but choices of agents, doses, and schedules vary. The selected regimen should adhere to the prognostic and stratification schemes described in the trial chosen for overall therapy.
        </p>
        <p>
         Choice of anthracycline and glucocorticoid may be influenced by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anthracycline
         </strong>
         – There is no preferred anthracycline.
         <a class="drug drug_pediatric" data-topicid="13207" href="/z/d/drug information/13207.html" rel="external">
          Daunorubicin
         </a>
         , which is associated with less cardiac toxicity ratio compared with
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         , is frequently used, particularly prior to allogeneic hematopoietic cell transplantation (HCT). Some institutions favor
         <a class="drug drug_pediatric" data-topicid="12617" href="/z/d/drug information/12617.html" rel="external">
          mitoxantrone
         </a>
         , based on a phase 3 trial that reported superior overall survival (OS) and progression-free survival (PFS) using mitoxantrone compared with daunorubicin [
         <a href="#rid14">
          14
         </a>
         ]; however, mitoxantrone is more cardiotoxic than doxorubicin and daunorubicin, making it less attractive for treatment in children with prior cumulative anthracycline exposure &gt;200 mg/m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid
         </strong>
         – The choice of glucocorticoid should be guided by the chosen protocol.
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          Dexamethasone
         </a>
         generally has greater anti-leukemic effect and better central nervous system (CNS) penetration than
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         , but it is associated with increased toxicity (eg, avascular necrosis), especially in adolescents [
         <a href="#rid115">
          115,116
         </a>
         ]. The current COG trial (AALL1821) uses dexamethasone.
        </p>
        <p>
        </p>
        <p>
         Administration and toxicity of components of the core reinduction regimen are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Remission induction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1403635837">
         <span class="h3">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nelarabine
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          Nelarabine
         </a>
         is a purine nucleoside prodrug that is converted in vivo to ara-GTP. It has shown efficacy as a single agent for the treatment of relapsed or refractory (r/r) T cell ALL/LBL in children and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overall response rate (ORR) with
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         monotherapy was 55 percent for the first relapse and 27 percent for the second relapse in children and adolescents [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Administration and toxicity of
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          nelarabine
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">
          "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Nelarabine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">
          Nelarabine
         </a>
         is approved by the US Food and Drug Administration (FDA) for treatment of r/r T cell ALL/LBL in children and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bortezomib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         is a proteasome inhibitor that prevents degradation of misfolded proteins. Bortezomib was shown to synergize with steroids in preclinical studies [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Response rates of 68 to 73 percent were reported in very early relapse of B cell and T cell ALL/LBL, when combined with chemotherapy [
         <a href="#rid64">
          64,119
         </a>
         ].
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         has been tested in clinical trials for newly diagnosed T cell ALL/LBL [
         <a href="#rid68">
          68,69,119
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clofarabine
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          Clofarabine
         </a>
         <strong>
         </strong>
         is a deoxyadenosine analog that is approved by the US FDA for treatment of children (1 to 21 years) with r/r ALL/LBL who have experienced treatment failure with two prior regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Informative studies of
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          clofarabine
         </a>
         in children with r/r ALL/LBL include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multicenter study, 61 heavily pretreated children (1 to 20 years) received a median of three cycles of
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          clofarabine
         </a>
         and achieved an ORR of 30 percent (seven complete response [CR], five CR without platelet recovery, six partial remissions) [
         <a href="#rid120">
          120
         </a>
         ]. The most common grade ≥3 adverse events (AEs) were febrile neutropenia, anorexia, hypotension, and nausea.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective multicenter study reported 61 percent ORR (52 percent CR) among children treated with
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          clofarabine
         </a>
         alone or combined with other agents; half of the children were able to proceed to allogeneic HCT [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          Clofarabine
         </a>
         has been combined with other cytotoxic chemotherapy, including
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13197" href="/z/d/drug information/13197.html" rel="external">
          cytarabine
         </a>
         , but such regimens were associated with high rates of infections and other AEs [
         <a href="#rid122">
          122,123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of
         <a class="drug drug_pediatric" data-topicid="12924" href="/z/d/drug information/12924.html" rel="external">
          clofarabine
         </a>
         in adults with r/r ALL/LBL is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">
          "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Clofarabine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2801414763">
         <span class="h2">
          Blinatumomab (anti-CD19)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          Blinatumomab
         </a>
         is a bispecific T cell engager (BiTE) anti-CD3/CD19 monoclonal antibody that directs CD3+ effector memory T cells to CD19+ ALL/LBL tumor cells.
        </p>
        <p>
         The phase 3 trial (COG AALL1331) reported superior survival with
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         , compared with chemotherapy consolidation [
         <a href="#rid65">
          65
         </a>
         ], as described above. (See
         <a class="local">
          'Intermediate- or high-risk B cell'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          Blinatumomab
         </a>
         is approved by the US FDA for children with relapsed B-ALL/LBL.
        </p>
        <p class="headingAnchor" id="H13661178">
         <span class="h2">
          Inotuzumab ozogamicin (anti-CD22)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          Inotuzumab ozogamicin
         </a>
         was associated with 67 percent CR with r/r ALL/LBL, as part of a compassionate-use program in pediatric patients (age range of 2 to 21 years) [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         In a phase 3 trial in adults with r/r ALL/LBL, compared with standard intensive chemotherapy, treatment with
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          inotuzumab ozogamicin
         </a>
         achieved superior OS, PFS, CR, duration of remission, and measurable residual disease (MRD)-negative status [
         <a href="#rid103">
          103
         </a>
         ], as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">
          "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Inotuzumab ozogamicin'
         </a>
         .)
        </p>
        <p>
         Inotuzomab ozogamicin was granted fast-track approval by the US FDA and the European Medicines Agency (EMA) for adult patients with r/r ALL/LBL. However, inotuzumab has been associated with hepatic sinusoidal obstruction syndrome (SOS; also called veno-occlusive disease) both pre- and post-HCT, resulting in the closure and dose reduction of two contemporary clinical trials.
        </p>
        <p>
         Use of inotuzomab ozogamicin in adults is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">
          "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Inotuzumab ozogamicin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H66624458">
         <span class="h2">
          CAR-T cell therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chimeric antigen receptor (CAR)-T cells are a form of genetically modified autologous immunotherapy that can be directed at B cell ALL/LBL. This is a customized treatment in which the individual's own T lymphocytes are genetically modified (transduced) with a gene that encodes a CAR to direct the patient's T cells against the leukemic cells, a process that takes four to eight weeks. The T cells are genetically modified ex vivo, expanded in a production facility, and then infused back into the patient.
        </p>
        <p>
         As with other immunotherapies, CAR-T cells depend on expression of their target antigen; loss of the target is a major mechanism by which tumor cells can escape immunotherapy, as discussed above. (See
         <a class="local">
          'Multiply relapsed B cell ALL/LBL'
         </a>
         above.)
        </p>
        <p>
         CAR-T cell therapy is associated with neurologic events and cytokine release syndrome (CRS; a systemic response with high fever, flu-like symptoms, hypotension, mental status changes). Facilities that dispense these products require special certification, staff must be trained to recognize and manage its adverse events, and
         <a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">
          tocilizumab
         </a>
         (a humanized monoclonal antibody against the interleukin 6 receptor) must be available for immediate administration. In the United States,
         <a class="drug drug_pediatric" data-topicid="117665" href="/z/d/drug information/117665.html" rel="external">
          tisagenlecleucel
         </a>
         is only available through a risk evaluation and mitigation strategy (REMS), and its label carries a boxed warning for neurologic events and for CRS. (See
         <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">
          "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'CAR-T'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="117665" href="/z/d/drug information/117665.html" rel="external">
          Tisagenlecleucel
         </a>
         is a CD19-directed CAR-T cell immunotherapy that may achieve long-term survival after r/r ALL/LBL, including those with low-level CNS disease. Early efficacy of CD19-redirected CAR T-cells in r/r ALL is well-established [
         <a href="#rid72">
          72,124-126
         </a>
         ]. Tisagenlecleucel was associated with 65 to 90 percent ORR for r/r pediatric ALL/LBL [
         <a href="#rid127">
          127
         </a>
         ]. Most studies show that 25 to 50 percent of patients who achieve CR with CAR-T cell therapy subsequently relapse; longer follow-up is needed to better define the relapse risk [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a single-center study, a single infusion of
         <a class="drug drug_pediatric" data-topicid="117665" href="/z/d/drug information/117665.html" rel="external">
          tisagenlecleucel
         </a>
         achieved 81 percent CR, and all patients who had a response were negative for MRD by flow cytometry [
         <a href="#rid72">
          72
         </a>
         ]. At six months, rates of OS and EFS were 90 and 73 percent, respectively; corresponding rates at 12 months were 76 and 50 percent. However, grade ≥3 AEs occurred in 73 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter trial of 63 pediatric and young adult patients reported an 83 percent overall remission rate (including 63 percent CR and 19 percent CR with incomplete hematologic recovery); all responding patients were negative for MRD by flow cytometry [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="117665" href="/z/d/drug information/117665.html" rel="external">
          Tisagenlecleucel
         </a>
         is approved by the US FDA for treatment of patients ≤25 years of age with primary refractory or second or later relapse of B cell ALL/LBL [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H358171475">
         <span class="h2">
          Allogeneic transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic HCT is considered the only modality that can reliably cure r/r ALL/LBL.
        </p>
        <p>
         We proceed to allogeneic HCT for most children with r/r ALL/LBL, including early and very early relapse, T cell ALL/LBL, and poor MRD response (note that threshold levels of MRD vary among research groups). Exceptions include [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late (&gt;18 months) isolated CNS or other extramedullary site (eg, testis) relapse
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late medullary (bone marrow) relapse (&gt;3 years) with MRD-negativity at end-of-induction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children who are medically-unfit for transplantation
        </p>
        <p>
        </p>
        <p>
         We pursue transplant using the best available donor, since survival rates are similar with HCT using human leukocyte antigen (HLA)-matched siblings, fully matched unrelated donors, and haploidentical donors [
         <a href="#rid131">
          131,132
         </a>
         ].
        </p>
        <p>
         Reports of allogeneic HCT for r/r ALL/LBL include retrospective studies that suggest patients with primary refractory disease or T cell ALL/LBL have superior outcomes with transplantation [
         <a href="#rid7">
          7,133-135
         </a>
         ]. In a study that compared transplantation versus chemotherapy alone, OS was similar for the 198 patients who underwent HCT (43 percent) and the 427 patients who received chemotherapy alone (41 percent). However, the effect of HCT on survival differed according to cytogenetic risk subgroup. As an example, children &lt;6 years with B cell ALL/LBL without
         <em>
          KMT2A
         </em>
         rearrangement (ie, low-risk) had higher OS when treated with chemotherapy, compared with HCT (73 versus 59 percent). By contrast, older children, those with elevated white blood cell counts, T cell ALL/LBL, and additional cytogenetic risk factors had higher OS with a matched related donor HCT rather than chemotherapy alone (59 versus 35 percent). A similar study in Europe showed that adolescents and young adults with T cell ALL/LBL also did better with allogeneic HCT compared with chemotherapy alone (67 versus 42 percent) [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2547323995">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119662.html" rel="external">
          "Society guideline links: Acute lymphoblastic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H960221502">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Descriptions
         </strong>
         – Relapsed and refractory (r/r) acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) are defined as follows (see
         <a class="local">
          'Descriptions'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary refractory ALL/LBL
         </strong>
         – Primary refractory leukemia refers to persistence of leukemic blasts in blood, marrow, or extramedullary site after four to six weeks of induction therapy; this is frequently defined as either &gt;1 percent blasts (M1 marrow morphology) or measurable residual disease (MRD) &gt;1 percent at the end of induction or the end of consolidation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Relapsed ALL/LBL
         </strong>
         – Recurrence of ALL/LBL at any point after achieving complete remission (CR).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Genetic causes of r/r ALL/LBL differ for B cell and T cell ALL/LBL. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – The pretreatment evaluation includes immunophenotype and cytogenetic/molecular features of leukemic blasts and prognostic stratification, based on clinical and pathologic features. (See
         <a class="local">
          'Clinical and laboratory evaluation'
         </a>
         above and
         <a class="local">
          'Prognostic stratification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment of r/r ALL/LBL involves remission reinduction therapy, central nervous system (CNS) management, and consolidation therapy (eg, immunotherapy, chemotherapy, and/or allogeneic hematopoietic cell transplantation [HCT]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment should adhere to a contemporary research protocol at a site with substantial experience in managing pediatric ALL/LBL. Participation in a clinical trial is encouraged.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CNS management
         </strong>
         – All children with r/r ALL/LBL should receive either prophylaxis or treatment of CNS involvement, according to clinical symptoms, findings from lumbar puncture, and/or imaging. (See
         <a class="local">
          'CNS management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reinduction therapy
         </strong>
         – We treat with a four-drug reinduction regimen (eg,
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12617" href="/z/d/drug information/12617.html" rel="external">
          mitoxantrone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="120130" href="/z/d/drug information/120130.html" rel="external">
          calaspargase pegol
         </a>
         ). Other agents may be added to the four-drug platform for children with certain pathologic features. (See
         <a class="local">
          'Reinduction therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Post-remission
         </strong>
         – Management varies with immunophenotype, risk group, and response to reinduction therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Low-risk disease B cell
         </strong>
         – We favor consolidation chemotherapy, as guided by the chosen research protocol.
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          Blinatumomab
         </a>
         may be added if there are additional high-risk features. (See
         <a class="local">
          'Low-risk B cell'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Intermediate/high-risk B cell
         </strong>
         – For children with ≤25 percent blasts at end-of-induction, we suggest
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         , rather than consolidation chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Intermediate- or high-risk B cell'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For children with &gt;25 percent marrow blasts at end-of-induction, we treat with
         <a class="drug drug_pediatric" data-topicid="113708" href="/z/d/drug information/113708.html" rel="external">
          blinatumomab
         </a>
         ,
         <a class="drug drug_general" data-topicid="114511" href="/z/d/drug information/114511.html" rel="external">
          inotuzumab ozogamicin
         </a>
         , or chimeric antigen receptor (CAR)-T cell therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          T cell
         </strong>
         – Management is guided by MRD status at end-of-induction; prompt allogeneic HCT for MRD-negative or other options to achieve MRD negativity for others. (See
         <a class="local">
          'T cell ALL/LBL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special scenarios
         </strong>
         – Philadelphia chromosome (Ph)-positive or Ph-like ALL/LBL and isolated CNS or extramedullary relapse are described above. (See
         <a class="local">
          'Special scenarios'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatments
         </strong>
         – Chemotherapy, immunotherapy, and allogeneic HCT are described above. (See
         <a class="local">
          'Treatment regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second or later relapse
         </strong>
         – Management of multiply relapsed ALL/LBL is guided by prior therapy, as described above. (See
         <a class="local">
          'Second or later relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pui CH, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 2015; 33:2938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 2020; 136:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchmann S, Schrappe M, Baruchel A, et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood 2022; 139:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oudot C, Auclerc MF, Levy V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111:5477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012; 19:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 2013; 162:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118:2077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 2013; 31:2736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczepanski T, van der Velden VH, Waanders E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol 2011; 29:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008; 112:4178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawamata N, Ogawa S, Seeger K, et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol 2009; 34:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet 2020; 395:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzoneva G, Dieck CL, Oshima K, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 2018; 553:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barz MJ, Hof J, Groeneveld-Krentz S, et al. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood 2020; 135:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 2015; 6:6604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang W, Park J, Kwon A, et al. CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia. Exp Mol Med 2019; 51:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012; 122:3398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010; 49:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005; 105:4849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Limbergen H, Beverloo HB, van Drunen E, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001; 30:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones CL, Gearheart CM, Fosmire S, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood 2015; 126:2202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roti G, Stegmaier K. New Approaches to Target T-ALL. Front Oncol 2014; 4:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:580.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surrey LF, MacFarland SP, Chang F, et al. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Med 2019; 11:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang F, Lin F, Cao K, et al. Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. J Mol Diagn 2019; 21:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22:2142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchey AK, Pollock BH, Lauer SJ, et al. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study . J Clin Oncol 1999; 17:3745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 2005; 130:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000; 108:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28:2339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood 2011; 117:3010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irving JA, Enshaei A, Parker CA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood 2016; 128:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, et al. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. J Clin Oncol 2019; 37:3493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu CH, Chang WT, Jou ST, et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci 2020; 111:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew G, Chen Y, Lu X, et al. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. Haematologica 2021; 106:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol 2008; 26:3971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reismüller B, Attarbaschi A, Peters C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol 2009; 144:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23:3376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwaan CM, Kowalczyk J, Schmitt C, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol 2017; 179:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock JA, Malvar J, Dalla-Pozza L, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer 2022; 69:e29901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton TM, Perentesis JP, Gamis AS, et al. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 2015; 125:1759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moorman AV, Schwab C, Winterman E, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol 2020; 191:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 2018; 320:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 2014; 61:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskarsson T, Söderhäll S, Arvidson J, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica 2016; 101:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker C, Krishnan S, Hamadeh L, et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol 2019; 6:e204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton TM, Lu X, O'Brian MM, et al. Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1) [Abstract]. J Clin Oncol 2013; 31:a10003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA 2021; 325:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol 2022; 40:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton TM, Whitlock JA, Lu X, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol 2019; 186:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol 2022; 40:2106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010; 28:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun W, Malvar J, Sposto R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp; lymphoma study. Leukemia 2018; 32:2316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018; 378:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol 2019; 5:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol 2014; 4:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood 2017; 129:3352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts KG, Yang YL, Payne-Turner D, et al. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Adv 2017; 1:1657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaranta BP, Halperin EC, Kurtzberg J, et al. The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation. Cancer 2004; 101:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barredo JC, Devidas M, Lauer SJ, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 2006; 24:3142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masurekar AN, Parker CA, Shanyinde M, et al. Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial. PLoS One 2014; 9:e108107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hastings C, Chen Y, Devidas M, et al. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. Pediatr Blood Cancer 2021; 68:e29256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harker-Murray PD, Thomas AJ, Wagner JE, et al. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transplant 2008; 14:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barredo JC, Hastings C, Lu X, et al. Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 2018; 65:e26928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pehlivan KC, Duncan BB, Lee DW. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. Curr Hematol Malig Rep 2018; 13:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goulden N, Langlands K, Steward C, et al. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol 1994; 87:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagedorn N, Acquaviva C, Fronkova E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007; 110:4022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckert C, von Stackelberg A, Seeger K, et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer 2013; 49:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008; 22:2193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabelli M, Zecca M, Messina C, et al. Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children. Bone Marrow Transplant 2019; 54:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sedig LK, Spruit JL, Southwell J, et al. Palliative care is not associated with decreased intensity of care: Results of a chart review from a large children's hospital. Pediatr Blood Cancer 2022; 69:e29391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato M, Horikoshi Y, Okamoto Y, et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant 2012; 47:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lund TC, Ahn KW, Tecca HR, et al. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant 2019; 25:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naik S, Martinez C, Leung K, et al. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant 2015; 21:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaniv I, Krauss AC, Beohou E, et al. Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biol Blood Marrow Transplant 2018; 24:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotillo E, Barrett DM, Black KL, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 2015; 5:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 2018; 24:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv 2019; 3:3539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia 2019; 33:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol 2010; 150:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diorio C, Teachey DT. Harnessing immunotherapy for pediatric T-cell malignancies. Expert Rev Clin Immunol 2020; 16:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018; 131:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pikman Y, Alexe G, Roti G, et al. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res 2017; 23:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawai CM, Freund J, Oh P, et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 2012; 22:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 2016; 128:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suryani S, Carol H, Chonghaile TN, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res 2014; 20:4520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov 2021; 11:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durinck K, Goossens S, Peirs S, et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol 2015; 43:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habets RA, de Bock CE, Serneels L, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Möricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011; 25:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006; 58:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) Study. Blood 2012; 120:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24:1917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011; 154:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118:6043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatr Blood Cancer 2013; 60:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017; 129:3322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood 2020; 135:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz L. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Front Immunol 2020; 11:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr 2018; 172:1161.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf (Accessed on February 01, 2018).
         </li>
         <li class="breakAll">
          https://www.fda.gov/downloads/UCM573941.pdf (Accessed on February 01, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balduzzi A, Dalle JH, Wachowiak J, et al. Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study. Biol Blood Marrow Transplant 2019; 25:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood 2018; 132:2594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006; 24:5742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111:2548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol 2015; 33:1265.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 138365 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22412151" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26304874" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589723" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : How I treat relapsed acute lymphoblastic leukemia in the pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34192312" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22494120" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Outcomes after induction failure in childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18349402" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18388178" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525580" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23808872" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predicting relapse risk in childhood acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21719599" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19212338" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131038" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775972" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21357790" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18768390" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19424578" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19039135" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32247396" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21390130" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : CREBBP mutations in relapsed acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29342136" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31971569" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25790293" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30635552" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472075" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12086890" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023710" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The molecular basis of T cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237151" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237106" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20228800" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : PHF6 mutations in T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873882" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20073070" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15713800" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11170285" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26324703" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072021" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : New Approaches to Target T-ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913532" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913532" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31133068" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical utility of custom-designed NGS panel testing in pediatric tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31255796" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18818707" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577846" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15982346" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759711" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385996" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193696" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27229005" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31644328" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31729120" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32001530" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18711187" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19077160" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15908649" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28771663" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35989458" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24976003" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25645356" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32926422" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30208456" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24424789" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26494838" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30826273" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1) [Abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33651090" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34767461" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064980" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30957229" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35271306" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19841326" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29728694" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia&amp;lymphoma study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29385370" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30703192" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24724051" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21220611" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19138562" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408464" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25207766" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296813" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308251" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Current management and challenges of malignant disease in the CNS in paediatric leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15305418" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16809737" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25279465" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34302704" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18489994" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29286562" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317870" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Chimeric antigen receptor T cells for sustained remissions in leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30120708" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947268" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17720883" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265714" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18754029" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29899572" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34606158" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Palliative care is not associated with decreased intensity of care: Results of a chart review from a large children's hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367344" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Second allogeneic hematopoietic SCT for relapsed ALL in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30244103" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25765555" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29548831" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26516065" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30275569" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31738832" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30267011" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27292104" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20528871" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32103690" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Harnessing immunotherapy for pediatric T-cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305553" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28151717" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23079656" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27343252" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085673" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25013123" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33593877" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26123366" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Novel biological insights in T-cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31142678" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26888258" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527934" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16292537" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420992" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22653976" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia&amp;Lymphoma (TACL) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16622268" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21689087" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21967976" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335239" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155426" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408462" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31899793" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32849662" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30304407" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30304407" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30304407" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319153" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30348653" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Unrelated donor vs HLA-haploidenticalα/βT-cell- and B-cell-depleted HSCT in children with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179108" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039957" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25753432" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
